Mainz Biomed B.V. (MYNZ)
5.20
0.53 (11.35%)
At close: Jan 14, 2025, 3:59 PM
5.29
1.73%
Pre-market Jan 15, 2025, 04:35 AM EST
undefined% (undefined)
| Bid | 5.08 |
| Market Cap | 11.55M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -44.4 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 5.29 |
| Volume | 75,822 |
| Avg. Volume (20D) | 2,623,757 |
| Open | 4.68 |
| Previous Close | 4.67 |
| Day's Range | 4.66 - 5.34 |
| 52-Week Range | 0.18 - 7.95 |
| Beta | undefined |
About MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Nov 5, 2021
Employees 65
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Website https://mainzbiomed.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MYNZ stock is "Hold." The 12-month stock price forecast is $3, which is a decrease of -42.31% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
3 weeks ago ·
Source
+26.19%
Mainz Biomed shares are trading higher after the c...
Unlock content with
Pro Subscription
2 months ago ·
Source
+28.72%
Mainz Biomed shares are trading higher after the company announced it signed a collaboration agreement with Thermo Fisher Scientific to develop and potentially commercialize its Next Generation colorectal cancer screening product.
